Table A3.
MiRNAs that are known for their tumor suppressor and oncogenic potential (TS/O). Selected miRNAs are also involved in cardioprotection (CP). Targets are given for each miRNA, with no claim to completeness. Pubmed IDs (PMIDs) are given as references when no doi numbers are available.
| MiRNA Function | MiRNA Name | CB-MSC-EV [dCT ± SD] | AT-MSC-EV [dCT ± SD] | Fold Difference | p-Value | Confirmed Targets GeneGLOBE ID | Cell/Tissue/Cancer Type | MiRNA Cluster | Biological Effect | Reference |
|---|---|---|---|---|---|---|---|---|---|---|
| TS/O | miR-31-3p | 4.93 ± 0.56 | 5.08 ± 0.49 | –1.11 | 0.64 | RASA1 | colorectal carcinoma | — | oncomiR (promotes cell proliferation, tumor progression) | doi:10.1074/jbc.M112.367763 |
| SEMA4C | cervical cancer | — | tumor suppressor (chemoresistance) | doi:10.1038/s41598-019-54177-z | ||||||
| TIAM1 | colorectal carcinoma | miR-21 | oncomiR (promotes epithelial–mesenchymal transition, invasion) | doi:10.1074/jbc.M110.160069 | ||||||
| TS/O | miR-199b-5p | 4.39 ± 1.5 | 3.73 ± 0.43 | 1.58 | 0.53 | HER2 | osteosarcoma | — | oncomiR (promotes tumor progression) | PMID: 30610808 |
| STON2 | papillary thyroid carcinoma | — | tumor suppressor (metastasis, suppresses epithelial–mesenchymal transition) | doi:10.1002/iub.1889 | ||||||
| DYRK1A, NOTCH1, JAG1 | — | — | promotes pathological myocardial remodeling | doi:10.1016/j.ncrna.2016.12.002 | ||||||
| KLK10 | cervical cancer | — | oncomiR (promotes cell proliferation, metastasis) | doi:10.1016/j.bbrc.2018.05.165 | ||||||
| mTOR | endometrial endometrial adenocarcinoma | miR-100-5p, miR-199a-3p | tumor suppressor (cell autophagy) | PMID: 31966798 | ||||||
| GSK3B | monocytes | — | inhibition of NFkB signaling, anti-inflammatory | doi:10.1007/s10753-018-0799-2 | ||||||
| JAG1 | ligamentum flavum cells | — | inhibition of osteogenic differentiation | doi:10.1111/jcmm.13047 | ||||||
| CAV1 | non-small cell lung carcinoma | — | oncomiR (promotes cell proliferation) | doi:10.1038/s41419-019-1740-9 | ||||||
| ALK1 | breast cancer | — | tumor suppressor (angiogenesis) | doi:10.3389/fgene.2019.01397 | ||||||
| DDR1 | breast cancer | — | tumor suppressor (cell proliferation, invasion, metastasis) | doi:10.3892/ol.2018.9255 | ||||||
| BICC1 | oral cancer | miR-101-3p (not detected) |
tumor suppressor (cell autophagy) | doi:10.1016/j.mcp.2020.101567 | ||||||
| MLK | pancreatic beta cells | — | increases cell proliferation | doi:10.2174/2211536605666160607082214 | ||||||
| JAG1, DDR1 | colorectal carcinoma | — | tumor suppressor (cell proliferation, invasion) | doi:10.1002/path.5238 | ||||||
| PODXL, DDR1 | acute myeloid leukemia | — | tumor suppressor (cell proliferation) | doi:10.1002/ajh.23129 | ||||||
| HES1 | medulloblastoma | — | tumor suppressor (impairs cancer stem cell function) | doi:10.1371/journal.pone.0004998 | ||||||
| ITGA3 | squamous cell carcinoma | miR-199a-3p/5p | tumor suppressor (cell proliferation) | doi:10.1111/cas.13298 | ||||||
| TS/O | miR-221-3p | 1.25 ± 0.67 | 0.65 ± 0.25 | 1.51 | 0.11 | AXIN2 | - | miR-15b-5p | oncomiR (promotes cell proliferation, invasion) | doi:10.3892/ol.2019.11056 |
| THBS2 | squamous cell carcinoma | — | oncomiR (promotes angiogenesis) | doi:10.1007/s10456-019-09665-1 | ||||||
| SDF1 | cartilage | — | prevent cartilage degradation in osteoarthritis | doi:10.1007/s00109-017-1516-6 | ||||||
| VASH1 | squamous cell carcinoma | — | oncomiR (promotes metastasis) | doi:10.1038/s41388-018-0511-x | ||||||
| THBS1 | trophoblast | — | promotes invasion and proliferation | doi:10.1016/j.biopha.2018.10.009 | ||||||
| JAK3 | macrophages | — | regulates M1 to M2 transition | doi:10.3389/fimmu.2019.03087 | ||||||
| ARF4 | epithelial ovarian cancer | — | tumor suppressor (cell proliferation, metastasis) | doi:10.1016/j.bbrc.2017.01.002 | ||||||
| THBS2 | squamous cell carcinoma | — | oncomiR (promotes metastasis) | doi:10.1038/s41419-017-0077-5 | ||||||
| MMP22 | macrophages | — | prevent low-density lipoprotein-induced oxidative stress | doi:10.1002/jcb.27917 | ||||||
| EIF5A2 | medulloblastoma | — | tumor suppressor (cell proliferation, enhances apoptosis) | doi:10.1080/09168451.2018.1553604 | ||||||
| PTEN | gastric cancer | — | oncomiR (promotes tumor progression) | doi:10.3727/096504016 × 14756282819385 | ||||||
| TIMP3 | retina | — | promotes microvascular dysfunction | doi:10.1007/s00424-020-02432-y | ||||||
| PARP1 | breast cancer | — | tumor suppressor (tumor progression) | doi:10.18632/oncotarget.21561 | ||||||
| RB1 | pancreatic cancer | — | oncomiR (chemoresistance) | doi:10.1007/s13277-016-5445-8 | ||||||
| JNK1, TGFBR1, ETS-1 | cardiac fibroblasts | — | cardioprotective (inhibits fibroblast activation) | doi:10.1161/HYPERTENSIONAHA.117.10094 | ||||||
| TS/O, CP | miR-25-3p | 4.52 ± 0.53 | 4.8 ± 0.13 | –1.21 | 0.33 | BTG2 | breast cancer | — | tumor suppressor (cell proliferation) | doi:10.1186/s12943-017-0754-0 |
| PTEN | retinoblastoma | — | oncomiR (promotes tumor progression) | doi:10.1016/j.biopha.2019.109111 | ||||||
| FBXW7, DKK3 | glioma cells | — | oncomiR (promotes cell proliferation, metastasis) | doi:10.3892/etm.2019.7583 | ||||||
| BTG2 | breast cancer | — | oncomiR (promotes cell proliferation, metastasis) | doi:10.1155/2019/7024675 | ||||||
| SEMA4C | cervical cancer | — | tumor suppressor (suppresses EMT) | doi:10.1111/cas.13104 | ||||||
| ADAM10 | endothelial cells | — | inhibit NFkB Signaling and reduces inflammation | doi:10.3389/fimmu.2019.02205 | ||||||
| EZH2 | cardiomyocytes | — | cardioprotective (inhibit cardiomyocyte apoptosis during injury) | doi:10.1080/0886022X.2020.1745236 | ||||||
| TS/O | miR-23b-3p | 0.73 ± 0.69 | 1.02 ± 0.26 | –1.23 | 0.307825 | SIRT1 | lens epithelial cells | — | reduces apoptosis in oxidative stress | doi:10.1002/jcb.29270 |
| TGFBR3 | atrial fibroblasts | miR-27b-3p | promote atrial fibrosis in atrial fibrillation | doi:10.1111/jcmm.14211 | ||||||
| CB1R | gastric cancer | miR-130a-5p (not detected) |
tumor suppressor (cell proliferation) | doi:10.2147/OTT.S181706 | ||||||
| ANXA2 | pancreatic ductal adenocarcinoma | — | tumor suppressor (cell proliferation) | doi:10.1159/000494468 | ||||||
| ETS1 | hepatocytes | — | downregulate Apo(a) expression | doi:10.1002/cbin.10896 | ||||||
| PGC1A | osteosarcoma | — | oncomiR (promotes cell proliferation) | doi:10.1038/s41419-019-1614-1 | ||||||
| EBF3 | squamous cell carcinoma | — | oncomiR (promotes cell proliferation, metastasis) | doi:10.1093/abbs/gmy049 | ||||||
| ZEB1 | hepatocellular carcinoma | — | tumor suppressor (suppresses epithelial–mesenchymal transition) | doi:10.1016/j.gene.2018.05.061 | ||||||
| CMET | cervical cancer | — | tumor suppressor (cell proliferation, invasion, metastasis) | doi:10.1038/s41598-020-60143-x | ||||||
| ATG12, HMGB2 | gastric cancer | — | tumor suppressor (chemosensitivity) | doi:10.1038/cddis.2015.123 | ||||||
| HS6ST2 | chondrocytes | — | enhances matrix degradation in osteoarthritis | doi:10.1038/s41419-018-0729-0 | ||||||
| TGIF1 | keratinocytes | — | regulation of keratinocyte differentiation | doi:10.1111/exd.13119 | ||||||
| PTEN | renal cancer | — | oncomiR (promotes cell proliferation) | doi:10.1371/journal.pone.0050203 | ||||||
| TS/O, CP | miR-27b-3p | 2.97 ± 0.79 | 2.77 ± 0.5 | 1.15 | 0.84 | TGFBR3 | atrial fibroblasts | miR-27b-3p | promote atrial fibrosis in atrial fibrillation | doi:10.1111/jcmm.14211 |
| HOXA10 | colorectal carcinoma | — | oncomiR (promotes cell invasion, metastasis) | doi:10.1042/BSR20191087 | ||||||
| CBLB, GRB2 | breast cancer | — | tumor suppressor (cell proliferation, chemoresistance) | doi:10.1038/s41419-017-0211-4 | ||||||
| WNT3A | atrial fibroblasts | — | cardioprotection (reduces atrial fibrosis during atrial fibrillation) | doi:10.1155/2019/5703764 | ||||||
| MARCH7 | endometrial carcinoma | — | tumor suppressor (cell proliferation, invasion, metastasis) | doi:10.1093/abbs/gmz030 | ||||||
| SMAD7 | endothelial cells | — | suppresses endothelial cell proliferation and migration in Kawasaki disease | doi:10.1159/000492354 | ||||||
| HIPK2 | chondrocytes | — | inhibits apoptosis in rheumatoid arthritis | doi:10.1080/21691401.2019.1607362 | ||||||
| PPARG | thyroid cancer | — | oncomiR (chemoresistance) | doi:10.1111/bcpt.13076 | ||||||
| FZD7 | lung cancer | — | tumor suppressor (tumor progression) | PMID: 29028088 | ||||||
| SP7 | maxillary sinus membrane stem cells | — | suppress osteogenic differentiation | doi:10.1097/ID.0000000000000637 | ||||||
| LIMK1 | colorectal carcinoma | — | tumor suppressor (cell proliferation, invasion, metastasis) | PMID: 31966797 | ||||||
| GSPT1 | gastric cancer | — | tumor suppressor (tumor progression) | doi:10.1016/j.biopha.2019.109417 | ||||||
| YAP1 | glioma cells | — | tumor suppressor (tumorigenesis) | doi:10.1139/bcb-2019-0300 | ||||||
| ROR1 | gastric cancer | — | tumor suppressor (cell proliferation) | doi:10.1186/s13046-015-0253-3 | ||||||
| PPARG | oocytes | — | maturation | doi:10.1016/j.bbrc.2016.09.046 | ||||||
| GSPT1 | non-small cell lung carcinoma | — | tumor suppressor (cell proliferation, invasion, metastasis) | doi:10.2147/OTT.S196865 | ||||||
| NRF2 | squamous cell carcinoma | — | tumor suppressor (tumor progression) | doi:10.1007/s13577-020-00329-7 | ||||||
| TRAF3 | chondrocytes | — | inhibits IL1B-induced injury | doi:10.1016/j.intimp.2019.106052 | ||||||
| NR5A2, CREB1 | breast cancer | — | tumor suppressor (chemosensitivity) | doi:10.1038/cddis.2016.361 | ||||||
| TS/O, CP | miR-24-3p | 0.43 ± 0.62 | 1.48 ± 0.56 | –2.05 | 0.091 | KEAP1 | cardiomyocytes | — | cardioprotection (in ischemia-reperfusion injury) | doi:10.1155/2018/7042105 |
| FGF11 | T-cells | — | oncomiR (immune evasion) | doi:10.1002/path.4781 | ||||||
| SOX7 | lung cancer | — | oncomiR (promotes metastasis, invasion) | doi:10.1002/jcb.26553 | ||||||
| SOCS6 | prostate cancer | — | oncomiR (promotes metastasis, invasion, proliferation) | PMID: 31938287 | ||||||
| p27KIP1 | papillary thyroid carcinoma | — | oncomiR (promotes metastasis, invasion, proliferation) | doi:10.26355/eurrev_201907_18327 | ||||||
| BIM | breast cancer | — | oncomiR (chemoresistance) | doi:10.1002/jcb.28568 | ||||||
| RIPK1 | cardiomyocytes | — | cardioprotection (in ischemia-reperfusion injury) | doi:10.1159/000495161 | ||||||
| DEDD | bladder cancer | — | oncomiR (promotes tumor progression) | doi:10.3892/or.2016.5326 | ||||||
| PRKCH | Lacrimal adenoid cystic carcinoma | — | tumor suppressor (tumor progression) | doi:10.1371/journal.pone.0158433 | ||||||
| MTT1 | hepatocellular carcinoma | — | oncomiR (promotes cell proliferation) | doi:10.1002/cbf.3213 | ||||||
| SMAD5 | peridontal stem cells | — | inhibit osteogenic differentiation | doi:10.1002/jcp.27499 | ||||||
| JAB1/CSN5 | nasopharyngeal carcinoma | — | tumor suppressor (radiosensitivity) | doi:10.1038/onc.2016.147 | ||||||
| ATG4A | small cell lung cancer | — | tumor suppressor (chemosensitivity) | doi:10.18632/oncotarget.2787 | ||||||
| IGFBP5 | intervertebrate discs | — | induces disc degeneration | doi:10.1016/j.lfs.2020.117288 | ||||||
| NOTCH1, DLL1 | endothelial cells | — | inhibit angiogenesis after myocardial infarction | doi:10.3390/ijms21051733 | ||||||
| LAMB3 | pancreatic ductal adenocarcinoma | — | tumor suppressor (tumor progression) | doi:10.3389/fonc.2019.01499 | ||||||
| CHD5 | squamous cell carcinoma | — | oncomiR (promotes cell proliferation, chemoresistance) | doi:10.2217/fon-2016-0179 | ||||||
| FGF11 | fibroblasts | — | activation of fibrosis and proliferation in renal fibrosis | doi:10.1002/jcp.29329 | ||||||
| TS/O | miR-23a-3p | -0.14 ± 0.54 | 0.06 ± 0.95 | –1.14 | 0.99 | PNRC2 | renal cell carcinoma | — | oncomiR (promotes tumor progression) | doi:10.1016/j.biopha.2018.11.065 |
| KLF3 | melanoma | — | oncomiR (promotes tumor progression) | doi:10.1186/s12935-019-0927-6 | ||||||
| FGF2 | squamous cell carcinoma | — | tumor suppressor (cell proliferation) | doi:10.1016/j.prp.2018.12.021 | ||||||
| CHD17 | hepatocellular carcinoma | — | oncomiR (promotes cell proliferation) | doi:10.1007/s13105-020-00726-4 | ||||||
| SMAD3 | chondrocytes | — | promotes osteoarthritis | doi:10.1016/j.bbrc.2016.06.071 | ||||||
| PTEN | gliomal cells | — | oncomiR (promotes cell proliferation) | doi:10.1002/ar.24410 | ||||||
| TS/O, CP | miR-130a-3p | 4.86 ± 0.83 | 5.01 ± 0.74 | –1.11 | 0.75 | PDE4D | cardiomyocytes | — | cardioprotection (improves cardiac cell proliferation after myocardial infarction) | doi:10.1002/jcp.26327 |
| SMAD4 | esophageal cancer | — | oncomiR (promotes epithelial–mesenchymal transition) | doi:10.1002/cam4.1981 | ||||||
| RAB5B | breast cancer | — | tumor suppressor ( invasion, metastasis) | doi:10.1016/j.bbrc.2018.05.018 | ||||||
| SOX4 | non-small cell lung carcinoma | — | tumor suppressor (chemosensitivity) | doi:10.1080/15384047.2017.1385679 | ||||||
| SMAD4 | hepatoma cells | — | tumor suppressor (invasion, metastasis) | doi:10.1186/s13046-016-0296-0 | ||||||
| SNON | kidney | — | inhibition of renal fibrosis | doi:10.1016/j.yexmp.2019.104358 | ||||||
| TGFBR1/2 | hepatic stellate cells | — | decreases hepatic fibrosis | doi:10.1038/cddis.2017.10 | ||||||
| BACH2 | nasopharyngeal carcinoma | — | tumor suppressor (cell autophagy) | doi:10.1042/BSR20160576 | ||||||
| TS/O | miR-15a-5p | 5.52 ± 2.85 | 4.42 ± 1.07 | 2.14 | 0.73 | VEGFA | chondrocytes | — | aggravates osteoarthritis | doi:10.5582/bst.2016.01187 |
| VEGFA | peritoneal mesothelial cells | — | suppresses inflammation and fibrosis | doi:10.1002/jcp.27660 | ||||||
| WNT3A | endometrial carcinoma | — | tumor suppressor (cell growth) | PMID: 29164582 | ||||||
| CXCL10 | chronic myeloid leukemia | — | tumor suppressor (cell autophagy), metastasis | PMID: 28979704 | ||||||
| MYCN | neuroblastoma cells | miR-15b-5p, miR-16-5p | tumor suppressor (tumor progression) | doi:10.1002/1878-0261.12588 | ||||||
| PTHrP | chondrocytes | — | promotes osteoarthritis | doi:10.1155/2019/3904923 | ||||||
| FASN | arteries | — | alleviates atherosclerosis and vascular inflammation | doi:10.1042/BSR20181852 | ||||||
| PHLPP2 | gastric cancer | — | oncomiR (chemoresistance) | doi:10.4149/neo_2020_190904N861 | ||||||
| TP53INP1 | cervical cancer | — | oncomiR (anti-apoptotic) | doi:10.26355/eurrev_201910_19129 | ||||||
| BDNF | hepatocellular carcinoma | — | tumor suppressor (cell proliferation) | doi:10.1007/s13277-015-4427-6 | ||||||
| TGFB3, VEGF | retinal endothelial cells | — | promote endothelial cell tight junction formation | doi:10.1016/j.visres.2017.07.007 | ||||||
| VEGFA | endometrial mesenchymal stem cells | — | promote endometriosis | PMID: 27608888 | ||||||
| HOXA3 | thyroid cancer | — | tumor suppressor (tumor progression) | doi:10.1089/hum.2018.109 | ||||||
| TS/O, CP | miR-181a-5p | 5.5 ± 0.68 | 6.54 ± 0.7 | –1.09 | 0.9 | PBX1 | ligaments | — | promotes osteogenesis | doi:10.7150/thno.44309 |
| CBLB | esophageal cancer | — | tumor suppressor (chemosensitivity) | doi:10.2147/CMAR.S251264 | ||||||
| E2F7 | non-small cell lung carcinoma | — | oncomiR (tumor progression) | doi:10.2147/CMAR.S240964 | ||||||
| ESM1 | retina | — | anti-angiogenesis | doi:10.1002/jcp.29733 | ||||||
| SIRT1 | cardiomyocytes | — | promotes apoptosis in hypoxic injury | doi:10.1080/09168451.2020.1750943 | ||||||
| KLF17 | prostate cancer | — | oncomiR (promotes epithelial–mesenchymal transition) | PMID: 32195032 | ||||||
| PDGFRA | endothelial cells | — | anti-angiogenesis | doi:10.1002/cbf.3472 | ||||||
| AKT3 | gastric adenocarcinoma | — | tumor suppressor (cell proliferation, apoptosis) | doi:10.1098/rsob.190095 | ||||||
| p53 | cardiomyocytes | — | cardioprotection (reduces high glucose induced apoptosis) | doi:10.1538/expanim.19-0058 | ||||||
| ATG7 | hepatocellular carcinoma | — | oncomiR (inhibits autophagy) | doi:10.1002/jcb.29064 | ||||||
| TS/O | miR-106a-5p | 5.19 ± 0.76 | 5.42 ± 1.07 | –1.17 | 0.97 | HK2 | squamous cell carcinoma | — | tumor suppressor (cell proliferation, invasion, metastasis) | doi:10.1007/s11010-020-03840-5 |
| STAT3 | endothelial cells | — | allelviates atherosclerosis and vascular inflammation | doi:10.3892/mmr.2020.11147 | ||||||
| RBM24 | prostate cancer | — | oncomiR (tumor progression) | doi:10.2147/OTT.S246274 | ||||||
| TGFBR2 | colorectal carcinoma | — | oncomiR (chemoresistance) | PMID: 31949649 | ||||||
| ARHGAP24 | ovarian carcinoma | — | oncomiR (cell proliferation, invasion) | doi:10.1016/j.lfs.2020.117296 | ||||||
| TGFBR2 | palate | — | promotes cleft palate formation | doi:10.1016/j.yexcr.2019 | ||||||
| TS/O | miR-125a-5p | 2.3 ± 0.54 | 2.64 ± 0.22 | –1.27 | 0.27 | FUT4 | osteosarcoma | — | tumor suppressor (tumor progression) | doi:10.3389/fgene.2020.00672 |
| LIN28B | ovarian carcinoma | — | tumor suppressor (cell proliferation, metastasis) | doi:10.3892/mmr.2020.11223 | ||||||
| MACC1 | hepatocellular carcinoma | miR-34a | tumor suppressor (cell proliferation, metastasis) | doi:10.4149/neo_2020_191019N1062 | ||||||
| FNDC3B | colorectal carcinoma | miR-217 | oncomiR (cell proliferation, invasion) | doi:10.2147/OTT.S226520 | ||||||
| HK2 | lung | — | inhibits glycolysis and improved pulmonary arterial hypertension | doi:10.18632/aging.103163 | ||||||
| TRAF6 | macrophages | — | promotes M2 polarization | doi:10.1007/s10753-020-01231-y | ||||||
| GALNT7 | cervical cancer | — | tumor suppressor (cell proliferation, invasion) | doi:10.1186/s12935-020-01209-8 | ||||||
| VEGFA | trophoblast | — | suppresses migration and proliferation | doi:10.1016/j.bbrc.2020.02.137 | ||||||
| GAB2 | breast cancer | — | tumor suppressor (cell proliferation, invasion) | doi:10.3934/mbe.2019347 | ||||||
| SIRT7 | non-small cell lung carcinoma | — | tumor suppressor (radioresistance) | doi:10.3233/CBM-190381 | ||||||
| TAZ | ovarian carcinoma | — | tumor suppressor (inhibits epithelial–mesenchymal transition) | doi:10.3233/CBM-190381 | ||||||
| TS/O, CP | miR-125b-5p | −1.36 ± 0.51 | −1.21 ± 0.36 | –1.11 | 0.58 | p53, BAK1 | cardiomyocytes | — | cardioprotection (inhibits apoptosis in ischemia-reperfusion injury) | doi:10.7150/thno.28021 |
| p53, BNIP3 | cardiomyocytes | — | cardioprotection (inhibits apoptosis in ischemia-reperfusion injury) | doi:10.1161/CIRCRESAHA.118.312758 | ||||||
| SMAD7 | cardiomyocytes | — | cardiotoxic (increase hypoxia induced injury signaling) | doi:10.3892/ijmm.2018.3496 | ||||||
| BAK1, KLF13 | cardiomyocytes | — | cardioprotection (inhibits apoptosis in ischemia-reperfusion injury) | doi:10.1016/j.yjmcc.2017.11.003 | ||||||
| EIF5A2 | melanoma | — | tumor suppressor (cell proliferation, metastasis) | doi:10.1186/s13046-020-01599-7 | ||||||
| BTG2 | lung adenocarcinoma | — | oncomiR (cell proliferation, migration and promotes epithelial–mesenchymal transition) | doi:10.26355/eurrev_202004_20841 | ||||||
| PAK3 | prenatal follicles | — | inhibits steroidogenesis | doi:10.1016/j.metabol.2020.154241 | ||||||
| BACE1 | neurons | — | attenuate neurotoxicity | doi:10.1016/j.jns.2020.116793 | ||||||
| TRIB2 | squamous cell carcinoma | — | tumor suppressor (tumor progression) | doi:10.1042/BSR20193172 | ||||||
| PDK1 | cervical cancer | — | tumor suppressor (tumorigenesis) | doi:10.1155/2020/4351671 | ||||||
| NLRC5 | cardiomyocytes | — | cardioprotection (inhibits apoptosis in ischemia-reperfusion injury) | doi:10.3892/etm.2019.8309 | ||||||
| STAT3 | embryonic stem cells | — | tumor suppressor (tumorigenesis) | doi:10.7150/jca.33696 | ||||||
| TRAF6 | skeletal muscle | — | relieves skeletal muscle atrophy | doi:10.21037/atm.2019.08.39 | ||||||
| HK2 | bladder cancer | — | tumor suppressor (tumor progression) | doi:10.1007/s13577-019-00285-x | ||||||
| AKT3 | keratinocytes | miR-181b-5p (not tested) |
inhibit proliferation | doi:10.1016/j.ejphar.2019.172659 | ||||||
| LIMK1 | brain | — | neuroprotection | doi:10.2174/1567202616666190906145936 | ||||||
| TXNRD1 | hepatocellular carcinoma | — | tumor suppressor (cell proliferation, invasion, metastasis) | doi:10.1186/s12935-019-0919-6 | ||||||
| TRAF6 | chondrocytes | — | anti-inflammatory in the setting of osteoarthritis | doi:10.1038/s41598-019-42601-3 | ||||||
| TS/O, CP | miR-19a-3p | 3.07 ± 0.62 | 3.29 ± 1.04 | –1.16 | 0.99 | PTEN | brain | — | alleviates ischemia-reperfusion injury-induced apoptosis | doi:10.1016/j.neuroscience.2020.04.020 |
| IGFBP3 | brain | — | alleviates ischemia-reperfusion injury | doi:10.1186/s40659-020-00280-9 | ||||||
| FAS | rectal cancer | — | tumor suppressor (induces apoptosis) | doi:10.1177/1533033820917978 | ||||||
| PIK3IP1 | hepatocellular carcinoma | — | tumor suppressor (cell proliferation) | doi:10.7150/jca.37748 | ||||||
| FOXF2 | colorectal carcinoma | — | tumor suppressor (inhibits epithelial–mesenchymal transition) | doi:10.3748/wjg.v26.i6.627 | ||||||
| IGFBP3 | ovarian carcinoma | — | oncomiR (tumor progression) | doi:10.1002/mc.23113 | ||||||
| SOCS3 | synovial cells | — | promote cell proliferation | 10.1002/jcb.28442 | ||||||
| PTEN | osteosarcoma | — | oncomiR (chemoresistance) | doi:10.3892/ol.2018.9592 | ||||||
| PFN1 | hepatocellular carcinoma | — | oncomiR (tumor progression) | doi:10.1016/j.prp.2018.12.012 | ||||||
| PTEN | hepatocellular carcinoma | — | oncomiR (chemoresistance, metastasis) | doi:10.1016/j.biopha.2018.06.097 | ||||||
| PITX1 | gastric cancer | — | oncomiR (tumor progression) | doi:10.1159/000489590 | ||||||
| TSC1 | osteoblasts | — | mediates dexamethasone resistance | doi:10.18632/oncotarget.23326 | ||||||
| SMAD2/4 | prostate cancer | — | tumor suppressor (invasion, metastasis) | doi:10.3892/or.2017.6096 | ||||||
| TGFBR2 | cardiac fibroblasts | miR-19b-3p | cardioprotection: anti-fibrotic | doi:10.1038/srep24747 | ||||||
| TS/O, CP | miR-19b-3p | 3.29 ± 0.35 | 3.07 ± 0.81 | 1.16 | 0.47 | NRP1 | gastric cancer | — | tumor suppressor (tumor progression) | doi:10.1186/s12935-020-01257-0 |
| CCDC6 | cholangiosarcoma | — | oncomiR (promotes proliferation, epithelial–mesenchymal transition) | doi:10.1016/j.abb.2020.108367 | ||||||
| HIF1A | endothelial cells | — | anti-angiogenic after hypoxia | doi:10.1096/fj.201902434R | ||||||
| BACE1 | brain | miR-16-5p | prevent amyloid beta induced apoptosis | doi:10.1097/WNR.0000000000001379 | ||||||
| TNFAIP3 | endothelial cells | — | pro-inflammatory in the setting of meningitis | doi:10.3390/pathogens8040268 | ||||||
| HOXA9 | non-small cell lung carcinoma | — | oncomiR (promotes proliferation, migration, invasion) | doi:10.2147/OTT.S216320 | ||||||
| PTEN | pancreatic cancer | — | oncomiR (cell proliferation) | doi:10.21037/atm.2019.04.61 | ||||||
| GRK6 | chondrocytes | — | reduces inflammation and matrix degradation | doi:10.1007/s11010-019-03563-2 | ||||||
| PTEN | muscle cells | — | osteogenic differentiation | doi:10.1002/cbin.11133 | ||||||
| TS/O CP | miR-214-3p | 2.19 ± 1.04 | 1.96 ± 0.59 | 1.17 | 0.99 | PTEN | cardiomyocytes | — | cardioprotection: inhibiting autophagy in sepsis | doi:10.1155/2020/1409038 |
| ATM | lung | — | reduce radiation induced pulmonary injury | doi:10.1089/ars.2019.7965 | ||||||
| CENPM | hepatocellular carcinoma | — | tumor supressor (tumor progression) | doi:10.1093/jb/mvaa073 | ||||||
| PLAGL2 | colorectal carcinoma | — | tumor suppressor (cell proliferation) | doi:10.18632/aging.103233 | ||||||
| LIVIN | colorectal carcinoma | — | tumor supressor (tumor progression) | doi:10.1080/21655979.2020 | ||||||
| IL17 | myocardium | — | cardioprotective (anti-fibrotic) | doi:10.3389/fcell.2020.00243 | ||||||
| WNT23 | vascular smooth muscle cells | — | inhibits cell proliferation | doi:10.26355/eurrev_202003_20696 | ||||||
| ABCB1, XIAP | retinoblastoma | — | oncomiR (chemoresistance) | doi:10.2147/OTT.S235862 | ||||||
| PSMD10 | papillary thyroid carcinoma | — | tumor suppressor (tumor progression) | doi:10.1002/jcp.29557 | ||||||
| TWIST1 | endometrial carcinoma | — | tumor suppressor (inhibit epithelial–mesenchymal transition) | doi:10.2147/OTT.S181037 | ||||||
| LHX6 | ovarian carcinoma | — | oncomiR (tumorigenesis) | doi:10.3390/cancers11121917 | ||||||
| ST6GAL1 | breast cancer | — | oncomiR (cell proliferation, inhibit apoptosis) | doi:10.1007/s10616-019-00352-z | ||||||
| FOXP3 | breast cancer | — | oncomiR (cell proliferation) | doi:10.26355/eurrev_201910_19156 | ||||||
| HDGF | pancreatic cancer | — | tumor suppressor (chemosensitivity) | doi:10.2147/OTT.S222703 | ||||||
| BIRC5 | breast cancer | — | tumor suppressor (cell proliferation) | doi:10.26355/eurrev_201909_18856 | ||||||
| NLRC5 | myocardium | — | cardioprotection: anti-fibrotic | doi:10.1042/CS20190203 | ||||||
| CTNNB1 | preadipocytes | — | promote differentiation | doi:10.3390/ijms20081816 | ||||||
| TS/O | miR-222-3p | 2.34 ± 1.60 | 1.61 ± 0.57 | 1.66 | 0.50 | PUMA | non-small cell lung carcinoma | — | oncomiR (cell proliferation, inhibit apoptosis) | doi:10.1177/1533033820922558 |
| PDCD10 | ovarian carcinoma | — | tumor suppressor (inhibit epithelial–mesenchymal transition) | doi:10.7150/thno.43198 | ||||||
| GILZ | airway epithelial cells | — | ameliorates glucocorticoid induced inhibition of cell repair | doi:10.1080/10799893.2020.1742739 | ||||||
| IGF1 | bone marrow-derived MSCs | — | promote osteogenic differentiation | doi:10.1016/j.diabres.2020.108121 | ||||||
| TMP2 | renal clear cell carcinoma | — | oncomiR (tumor progression) | doi:10.3233/CBM-190264 | ||||||
| IRF2, INPP4B | acute myeloid leukemia | — | tumor suppressor (cell proliferation) | doi:10.1016/j.mcp.2020.101513 | ||||||
| CDKN1B | squamous cell carcinoma | — | oncomiR (tumorigenesis) | doi:10.1111/jop.12986 | ||||||
| PPP2R2A | large B-cell lymphoma | — | oncomiR (cell proliferation, inhibit apoptosis) | doi:10.1177/1533033819892256 | ||||||
| GAS5, PTEN | colorectal carcinoma | — | oncomiR (promotes cell proliferation, migration, invasion) | doi:10.1016/j.omtn.2019.06.009 | ||||||
| PDE3A | endothelial cells | miR-27a-3p | promote vascular integrity | doi:10.1007/s12035-018-1446-5 | ||||||
| TIMP3 | osteosarcoma | — | oncomiR (promote metastasis and invasion) | doi:10.2147/OTT.S175745 | ||||||
| PTEN | papillary thyroid carcinoma | — | oncomiR (inhibit apoptosis) | doi:10.18632/oncotarget.23336 | ||||||
| TS/O, CP | miR-26a-5p | 3.75 ± 0.54 | 4.06 ± 0.72 | –1.24 | 0.53 | RANBP9 | brain | — | inhibit injury induced apoptosis | doi:10.1016/j.acthis.2020.151571 |
| TLR4 | kidney | — | protect against diabetic nephropathy | doi:10.1074/jbc.RA120.012522 | ||||||
| HMGA2 | hepatocellular carcinoma | — | tumor suppressor (cell proliferation, promote apoptosis) | doi:10.2147/CMAR.S237752 | ||||||
| CTGF | macrophages | — | modulates TLR signaling upon activation | doi:10.1042/BSR20192598 | ||||||
| CREB1 | renal cell carcinoma | miR-27a-3p, miR-221-3p | tumor suppressor (cell proliferation, promote apoptosis) | doi:10.1038/s41598-020-63403-y | ||||||
| DYRK1A | brain | — | inhibit development Alzheimer’s disease | doi:10.2174/1567202617666200414142637 | ||||||
| WNT5A | gastric cancer | — | tumor suppressor (cell proliferation) | doi:10.2147/OTT.S241199 | ||||||
| ADAM17 | cardiomyocytes | — | cardioprotection (inhibit apoptosis) | doi:10.1007/s10863-020-09829-5 | ||||||
| COL10A1 | gastric cancer | — | tumor suppressor (cell proliferation, migration, and invasion) | doi:10.26355/eurrev_202002_20170 | ||||||
| HOXA5 | osteosarcoma | — | oncomiR (promotes cell proliferation, migration) | doi:10.2147/OTT.S232100 | ||||||
| PTEN | myocardium | — | cardioprotection (inhibits apoptosis in ischemia-reperfusion injury) | doi:10.1590/1414-431 × 20199106 | ||||||
| PTGS2 | joints | — | alleviate osteoarthritis | doi:10.1016/j.intimp.2019.105946 | ||||||
| AURKA | hepatocellular carcinoma | — | tumor suppressor (chemosensitivity) | doi:10.1177/1533033819851833 | ||||||
| WNT5A | papillary thyroid carcinoma | — | tumor suppressor (cell proliferation, migration, and invasion) | doi:10.2147/OTT.S205994 | ||||||
| PTEN | myocardium | — | cardioprotection (inhibits apoptosis in ischemia-reperfusion injury) | doi:10.26355/eurrev_201908_18661 | ||||||
| PTEN | synovial cells | — | promote cell proliferation and inhibit apoptosis | doi:10.1042/BSR20182192 | ||||||
| TS/O, CP | miR-27a-3p | 1.87 ± 0.98 | 1.80 ± 0.88 | 1.05 | 0.96 | SLIT2 | endothelial cells | — | promotes apoptosis, autophagy during inflammation | doi:10.1016/j.jss.2020.05.102 |
| SP7 | preosteoblasts | — | promotes differentiation | doi:10.3892/mmr.2020.11246 | ||||||
| TAB3 | kidney | — | promotes apoptosis during kidney injury | doi:10.1080/09168451.2020.1792760 | ||||||
| PDL1 | macrophages | — | oncomiR (promotes immune evasion of breast cancer) | doi:10.1111/jcmm.15367 | ||||||
| BNIP3 | pancreatic cancer | — | oncomiR (inhibits apoptosis) | doi:10.3892/ijmm.2020.4632 | ||||||
| SMURF2 | lung | — | anti-fibrotic after bleomycin exposure | PMID: 32538751 | ||||||
| TGFBR1 | cardiomyocytes | — | cardioprotection (inhibits apoptosis in ischemia-reperfusion injury) | doi:10.1155/2020/2016259 | ||||||
| FBXW7 | cervical cancer | — | oncomiR (tumor progression) | doi:10.2147/CMAR.S234897 | ||||||
| ICOS | lung adenocarcinoma | — | tumor suppressor (promotes antitumor immunity) | doi:10.1111/1759-7714.13411 | ||||||
| NOVA | gastric cancer | — | oncomiR (promotes epithelial–mesenchymal transition) | doi:10.3892/mmr.2020.10949 | ||||||
| BNIP3 | cardiomyocytes | — | cardioprotection (inhibits apoptosis in ischemia-reperfusion injury) | doi:10.1016/j.omtn.2019.11.017 | ||||||
| TS/O, CP | miR-29a-3p | 2.50 ± 0.87 | 1.64 ± 0.66 | 1.82 | 0.19 | E2F1 | ovarian carcinoma | — | oncomiR (promotes epithelial–mesenchymal transition) | doi:10.18632/aging.103388 |
| PTEN | aorta | — | promotes development of aortic aneurysms | doi:10.1002/jcp.29746 | ||||||
| DRP1 | myocardium | — | cardioprotection (prevent myocardial hypertrophy) | doi:10.2174/0929866527666200416144459 | ||||||
| COL4A2 | hepatocellular carcinoma | — | tumor suppressor (cell proliferation, migration, and invasion) | doi:10.1039/c9mt00266a | ||||||
| COL5A1 | breast cancer | — | tumor suppressor (cell proliferation, migration) | doi:10.1016/j.lfs.2019.117179 | ||||||
| TNFR1 | endothelial cells | — | reduces TNF-alpha injury response | doi:10.1016/j.omtn.2019.10.014 | ||||||
| TS/O, CP | miR-30b-5p | 5.04 ± 1.10 | 4.56 ± 0.62 | 1.40 | 0.62 | KIF18A | prostate cancer | — | oncomiR (radioresistance) | doi:10.1089/cbr.2019.3538. |
| MYBL2 | medulloblastoma | — | tumor suppressor (cell proliferation, promotes apoptosis) | doi:10.1136/jim-2020-001354 | ||||||
| CAMK2D | dermal papilla cells | — | inhibits proliferation | doi:10.1186/s12864-020-06799-1 | ||||||
| ASPP2 | breast cancer | — | oncomiR (cell proliferation, migration, and invasion) | doi:10.1155/2020/7907269 | ||||||
| PTAFR | myocardium | — | cardioprotection: anti-fibrotic | doi:10.26355/eurrev_202004_20869 | ||||||
| PPARGC1A | Huh-7 cells | — | regulate lipid metabolism | doi:10.1186/s12944-020-01261-3 | ||||||
| CTNNB1 | cardiomyocytes | — | cardiotoxic (increased apoptosis during myocardial injury) | doi:10.23736/S00264806.20.06565-9 | ||||||
| AVEN | cardiomyocytes | — | cardiotoxic (increased apoptosis during myocardial injury) | doi:10.1186/s11658-019-0187-4 | ||||||
| TS/O, CP | miR-31-5p | 1.42 ± 0.46 | 2.24 ± 0.74 | –1.76 | 0.15 | YAP | colorectal carcinoma | — | tumor suppressor (cell proliferation, metastasis, chemosensitivity) | doi:10.1016/j.yexcr.2020.112176 |
| FLOT1 | renal clear cell carcinoma | — | tumor suppressor (cell proliferation, promote apoptosis) | doi:10.2147/OTT.S254634 | ||||||
| HOXA7 | trophoblast | — | inhibit proliferation | doi:10.1111/jog.14344 | ||||||
| PEX5 | hepatocellular carcinoma | — | oncomiR (radioresistance) | doi:10.7150/thno.42371 | ||||||
| TNS1 | colon adenocarcinoma | — | oncomiR (tumor progression) | doi:10.18632/aging.103096 | ||||||
| PKCG | cardiomyocytes | — | cardioprotective, inhibit cardiomyocyte hypertrophy | doi:10.26355/eurrev_202002_20351 | ||||||
| PAN3 | cardiomyocytes | — | cardioprotective: attenuates doxorubicin induced cardiotoxicity | doi:10.1016/j.yjmcc.2020.02.009 | ||||||
| ETBR, VEGFA | endothelial cells | — | anti-angiogenic | doi:10.1016/j.lfs.2020.117306 | ||||||
| MEGEA3 | hepatocellular carcinoma | — | oncomiR (chemoresistance, cell proliferation) | doi:10.1016/j.omtn.2019.10.035 | ||||||
| LATS2 | colorectal carcinoma | — | oncomiR (chemoresistance) | doi:10.3390/cancers11101576 | ||||||
| MLH1 | renal cell carcinoma | — | oncomiR (chemoresistance) | doi:10.1002/ijc.32543 | ||||||
| VEGFA | gliomal cells | — | tumor suppressor (anti-angiogenic) | doi:10.1002/ijc.32483 | ||||||
| TS/O | miR-365a-3p | 3.99 ± 0.84 | 4.34 ± 0.67 | –1.27 | 0.43 | ABCC4 | gastric cancer | — | tumor suppressor (tumor progression) | doi:10.2147/OTT.S245557 |
| ADAM10 | colorectal carcinoma | — | tumor suppressor (cell proliferation, migration) | doi:10.7150/jca.42731 | ||||||
| CREL | pancreatic cancer | — | tumor suppressor (tumor progression) | doi:10.1016/j.canlet.2019.03.025 | ||||||
| TET1 | hepatocellular carcinoma | — | tumor suppressor (tumor progression, invasion) | doi:10.4149/neo_2018_171119N752 | ||||||
| USP33 | lung cancer | — | oncomiR (tumorigenesis) | doi:10.1186/s12935-018-0563-6 | ||||||
| TS/O | miR-93-5p | 5.04 ± 0.59 | 5.43 ± 0.62 | –1.31 | 0.39 | MAP3K2 | hepatocellular carcinoma | — | oncomiR (tumor progression) | doi:10.1038/s41388-020-01401-0 |
| RGMB | squamous cell carcinoma | — | oncomiR (migration and invasion) | doi:10.7150/jca.43854 | ||||||
| FOXA1 | colorectal carcinoma | — | oncomiR (radioresistance) | doi:10.1186/s13046-019-1507-2 | ||||||
| AHNAK | gastric cancer | — | oncomiR (promotes epithelial–mesenchymal transition) | doi:10.1186/s12935-019-1092-7 | ||||||
| PD-L1 | colorectal carcinoma | — | tumor suppressor (tumor progression) | doi:10.1002/cbin.11323 | ||||||
| FOXK2 | cervical cancer | — | oncomiR (tumor progression) | doi:10.1007/s43032-020-00140-7 | ||||||
| CASC2 | chondrocytes | — | inhibits apoptosis in osteoarthritis | doi:10.1186/s12891-019-3025-y | ||||||
| MMP2 | gliomal cells | — | tumor suppressor (cell proliferation, migration) | doi:10.26355/eurrev_201911_19446 | ||||||
| TS/O | let-7a-5p | 2.46 ± 0.96 | 2.79 ± 0.46 | –1.26 | 0.40 | SMAD2 | chondrocytes | — | promotes hypertrophic differentiation | doi:10.1152/ajpcell.00039.2020 |
| SAMD2 | lens epithelial cells | — | inhibits proliferation, migration and invasion | PMID: 32345785 | ||||||
| DUSP7 | breast cancer | — | tumor suppressor (chemoresistance) | doi:10.2147/CMAR.S238513 | ||||||
| BCLXL | lung cancer | — | tumor suppressor (cell autophagy) | doi:10.1016/j.omto.2019.08.010 | ||||||
| BCL2L1 | lung cancer | — | tumor suppressor (induce apoptosis) | doi:10.3389/fonc.2019.00808 | ||||||
| EGFR | breast cancer | — | oncomiR (chemoresistance) | doi:10.1002/iub.2075 | ||||||
| HMGA2 | kidney | — | promotes diabetic nephropathy | doi:10.3892/mmr.2019.10057 |